Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective? (Q38302729)

1 September 2017

Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective? (English)

1 reference

1 September 2017

1 reference

3

Laura J Havrilesky

1 reference

1 September 2017

Neil T Phippen

1

1 reference

1 September 2017

Charles A Leath

series ordinal

2

1 reference

1 September 2017

Jason C Barnett

series ordinal

4

1 reference

1 September 2017

language of work or name

English

0 references

publication date

9 November 2014

1 reference

1 September 2017

1 reference

1 September 2017

136

1 reference

1 September 2017

1

1 reference

1 September 2017

43-47

1 reference

Improved survival with bevacizumab in advanced cervical cancer

1 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553065

Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553065

A phase 3 trial of bevacizumab in ovarian cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553065

The ethics and reality of rationing in medicine

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553065

Healthcare rationing by proxy: cost-effectiveness analysis and the misuse of the $50,000 threshold in the US.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553065

European perspective on the costs and cost-effectiveness of cancer therapies

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553065

Development of WHO guidelines on generalized cost-effectiveness analysis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553065

Addressing the American health-care cost crisis: role of the oncology community

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553065

Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553065

Widening socioeconomic disparities in cervical cancer mortality among women in 26 states, 1993-2007.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553065

Incorporation of bevacizumab in the primary treatment of ovarian cancer

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553065

At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553065

Potential health and economic consequences of misplaced priorities

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553065

Long-term trends in cancer mortality in the United States, 1930-1998.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553065

Delivering affordable cancer care in high-income countries

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553065

1 October 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.11.003

10.1016/J.YGYNO.2014.11.003

7 January 2021

Identifiers

DOI

1 reference

1 September 2017

1 reference

1 September 2017

PubMed publication ID

25448456

1 reference